Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Radiation Induced Fibrosis
Interventions: Losartan 25 milligram capsule, Placebo; Drug
Lead sponsor: Shaw Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: Breast Cancer
Interventions: LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Lung Cancer, Skin Cancer
Interventions: Image guided radiation therapy; Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Hartford, Connecticut • Minneapolis, Minnesota • Charlotte, North Carolina + 1 more

Conditions: Dercum's Disease
Interventions: 10 mg CBL-514 per injection, 15 mg CBL-514 per injection; Drug
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Foot Ulcer
Interventions: Transforming Powder Dressing, Standard of care topical wound agents and dressings; Device · Other
Lead sponsor: ULURU Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Winter Park, Florida • Baltimore, Maryland + 6 more

Conditions: Psoriasis
Interventions: Enstilar, Deucravacitinib; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Trastuzumab Deruxtecan, Datopotamab Deruxtecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more

Conditions: Psoriasis
Interventions: Dietary Counseling; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hereditary Angioedema
Interventions: STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV); Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia, Photosensitivity Disorders
Interventions: 532 nm KTP laser; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Edina, Minnesota

Conditions: Psoriasis
Interventions: ILV-094; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Beverly Hills, California • Santa Monica, California • South Miami, Florida + 9 more

Conditions: Acne Vulgaris
Interventions: BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel; Drug
Lead sponsor: BioPharmX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: QS21, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions: Prevention Care Management; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 64 Years · Female only
Enrollment: 2,241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Interventions: Filsuvez; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 3 more

Conditions: Capillary Malformation, Port Wine Stain
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Thoracic Cancer, Genitourinary Cancer
Interventions: Clinician Nudge Email, Patient Nudge Letter and Share questionaire; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Blood test; Diagnostic Test
Lead sponsor: Immunis.AI; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Inflammation, Skin Inflammation, Aging
Interventions: CeraVe Moisturizing Cream, Vaseline; Other · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 70 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: 3-dimensional conformal accelerated partial breast irradiation; Radiation
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 45 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: HIV Infections, Lipodystrophy
Interventions: raltegravir; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Development of Real-time Image-guided Radiotherapy

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

Combination of Sotyktu and Enstilar for Plaque Psoriasis

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

A Study of STAR-0215 in Healthy Adult Participants

Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer

Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Effect of Laser Treatment on Capillary Malformations

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

SNAPS Breast Cancer Patient Study Breast Cancer Patients

Skin Barrier Function and Inflammation in Aging: The BIA Study

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

Raltegravir Therapy for Women With HIV and Fat Accumulation

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer